The Society for Immunotherapy of Cancer (SITC) hosted the Immunomodulation of Antibody-drug Conjugates Summit on Wednesday, June 26, 2024 from 11 a.m. – 3:30 p.m. EDT. This summit highlighted the current understanding of antibody-drug conjugates (ADCs) and their effects on the immune system and the tumor microenvironment. This open-door virtual educational event presented the current state and future directions of the field and feature participation of invited stakeholders involved in ADC research and development, including clinicians and researchers from academia and industry.
The research and use of antibody-drug conjugates (ADCs) to treat certain cancers have expanded dramatically in the last two years. 2023 brought the first FDA approval of an ADC combined with immune checkpoint blockade, and recent studies suggest that ADCs may modulate the immune system and enhance the anti-cancer immune response. The immuno-oncology field must explore the clinical and translational research surrounding ADCs and their role in immunomodulation, in order to effectively use and design ADCs and ADC-based therapies to improve patient outcomes.
The primary objective of the SITC Summit on Immunomodulation of ADCs is to elucidate the mechanistic aspects of ADC monotherapies and combination therapies. Secondary goals include exploring the effects of ADCs on the immune system, tumor microenvironment and anti-tumor immunity, reviewing clinical considerations for ADC-based therapies, discussing the rationale of using immunoconjugates for targeted cancer therapy.
Contact Development@sitcancer.org for more information on how your organization's support can help advance cancer immunotherapy and make "cure" a reality.
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Date: June 26, 202400:35:01
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Date: June 26, 202400:35:48
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Date: June 26, 202400:31:54
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Date: June 26, 202400:38:03
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Date: June 26, 202400:13:21
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Speaker: Sofia Genta, MD; Date: June 26, 202400:17:09
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Speaker: Michiel van der Heijden, MD, PhD; Date: June 26, 202400:15:24
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Speaker: Lorenzo Galluzzi, PhD; Date: June 26, 202400:15:10
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Speaker: Funda Meric–Bernstam, MD; Date: June 26, 202400:12:32
Meeting: SITC Summit on Immunomodulation of Antibody-drug Conjugates; Speaker: Greg Thurber, PhD; Date: June 26, 202400:21:31
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us